Citations

Clear

16281 citation(s) found for "Yu, David".

Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease
Wagemann, Olivia , Shi, Xinyu , Bittner, Tobias , Scelsi, Marzia A. , Farlow, Martin R. , Clifford, David B. , Santacruz, Anna , Aschenbrenner, Andrew J. , Hassenstab, Jason , Gordon, Brian A. , Coalier, Kelley A., Perrin, Richard J., Xiong, Chengjie , Li, Yan , Morris, John C. , Lah, James J., Berman, Sarah , Roberson, Erik D. , Dyck, Christopher H. van, Gauthier, Serge , Pariente, Jérémie , Mummery, Catherine J. , Day, Gregory S. , Ringman, John M. , Méndez, Patricio Chrem, Fox, Nick C. , Okhravi, Hamid , Chhatwal, Jasmeer P. , Xiong, Chengjie , Sims, John R. , Holdridge, Karen C. , Proctor, Nicholas K. , Yaari, R. , Andersen, Scott W. , Mancini, Michele , Unit, Dominantly Inherited Alzheimer Network–Trials, Daniels, Alisha , Courtney, Laura, Lu, Ruijin , Gremminger, Emily, Franklin, Erin , Jerome, Gina, Herries, Elizabeth, Baker, Bryce, Minton, Matthew, Goate, Alison , Picarello, Danielle M. , Hornbeck, Russ C. , Chen, Allison , Chen, Charles D., Jarman, Steve, Jackson, Kelley, Keefe, Sarah , Koudelis, Deborah, Massoumzadeh, Parinaz , Nicklaus, Joyce , Pulizos, Christine, Sabaredzovic, Edita, Smith, Hunter , Scott, Jalen , Simmons, Ashlee, Rizzo, Jacqueline, Barthélemy, Nicolas R. , Xu, Jinbin , Ikonomović, Snežana, Nadkarni, Neelesh K. , Graff‐Radford, Neill R. , Huey, Edward D. , Salloway, Stephen , Bechara, Jacob , Ryan, Natalie S. , Laske, Christoph , Hofmann, Anna, Kuder-Buletta, Elke, Gräber‐Sultan, Susanne, Obermueller, Ulrike, Roedenbeck, Yvonne, Sánchez‐Valle, Raquel , Vázquez, Silvia , Leon, Yudy Milena, Ramírez, Laura, Seyfried, Nicholas T. , Fagan, Anne M. , Mori, Hiroshi , Gordon, Brian A , Roberson, Erik , Sánchez-Valle, Raquel , Day, Gregory S , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Morris, John C , Aschenbrenner, Andrew J , Goate, Alison M , Berman, Sarah , Liu, Haiyan , Wang, Guoqiao , Supnet, Charlene , Benzinger, Tammie L.S. , Cruchaga, Carlos , Ibanez, Laura , Li, Yan, Dyck, Christopher H. van , Galasko, Douglas , Hsiung, Ging‐Yuek Robin , Brooks, William S. , George‐Hyslop, Peter St , Suzuki, Kazushi , Jucker, Mathias , Mancini, Michele, Llibre‐Guerra, Jorge J. , Bateman, Randall J. , McDade, Eric , Unit, Dominantly Inherited Alzheimer Network–Trials, Xu, Xiong, Stauber, Jennifer, Renton, Alan , Flores, Shaney , Joseph‐Mathurin, Nelly , McCullough, Austin , McKay, Nicole S. , Wáng, Qīng , Smith, Jennifer A. , Stout, Sarah Holtz , Karch, Celeste M. , Marsh, Jacob A. , Holtzman, David M. , Noble, James M. , Ikeuchi, Takeshi , Kasuga, Kensaku , Niimi, Yoshiki , Schofield, Peter R. , Martins, Ralph N. , Cash, David M. , Vöglein, Jonathan , Lee, Jae‐Hong , Roh, Jee Hoon , Rosa-Neto, Pedro , Allegri, Ricardo , Surace, Ezequiel , Lopera, Francisco Javier , Aguillon, David , Levey, Allan I. , Johnson, Erik C. B. , Masters, Colin L.

Mayo Clinic

JAMA Neurology | April 29, 2024 | Volume: 81 | Issue: 6 | Pages: 582

10.1001/jamaneurol.2024.0991 | PMID 38683602 Get It

Importance Effects of antiamyloid agents, targeting either fibrillar or soluble monomeric amyloid peptides, on downstream biomarkers in cerebrospinal fluid (CSF) and plasma are largely unknown in dominantly inherited Alzheimer disease (DIAD). Objective To investigate longitudinal biomarker changes of synaptic dysfunction, neuroinflammation, and neurodegeneration in individuals with DIAD who are receiving antiamyloid treatment. Design, Setting, and Participants From 2012 to 2019, the Dominantly Inherited Alzheimer Network Trial Unit (DIAN-TU-001) study, a double-blind, placebo-controlled, randomized clinical trial, investigated gantenerumab and solanezumab in DIAD. Carriers of gene variants were assigned 3:1 to either drug or placebo. The present analysis was conducted from April to June 2023. DIAN-TU-001 spans 25 study sites in 7 countries. Biofluids and neuroimaging from carriers of DIAD gene variants in the gantenerumab, solanezumab, and placebo groups were analyzed. Interventions In 2016, initial dosing of gantenerumab, 225 mg (subcutaneously every 4 weeks) was increased every 8 weeks up to 1200 mg. In 2017, initial dosing of solanezumab, 400 mg (intravenously every 4 weeks) was increased up to 1600 mg every 4 weeks. Main Outcomes and Measures Longitudinal changes in CSF levels of neurogranin, soluble triggering receptor expressed on myeloid cells 2 (sTREM2), chitinase 3–like 1 protein (YKL-40), glial fibrillary acidic protein (GFAP), neurofilament light protein (NfL), and plasma levels of GFAP and NfL. Results Of 236 eligible participants screened, 43 were excluded. A total of 142 participants (mean [SD] age, 44 [10] years; 72 female [51%]) were included in the study (gantenerumab, 52 [37%]; solanezumab, 50 [35%]; placebo, 40 [28%]). Relative to placebo, gantenerumab significantly reduced CSF neurogranin level at year 4 (mean [SD] β = −242.43 [48.04] pg/mL; P < .001); reduced plasma GFAP level at year 1 (mean [SD] β = −0.02 [0.01] ng/mL; P = .02), year 2 (mean [SD] β = −0.03 [0.01] ng/mL; P = .002), and year 4 (mean [SD] β = −0.06 [0.02] ng/mL; P < .001); and increased CSF sTREM2 level at year 2 (mean [SD] β = 1.12 [0.43] ng/mL; P = .01) and year 4 (mean [SD] β = 1.06 [0.52] ng/mL; P = .04). Solanezumab significantly increased CSF NfL (log) at year 4 (mean [SD] β = 0.14 [0.06]; P = .02). Correlation analysis for rates of change found stronger correlations between CSF markers and fluid markers with Pittsburgh compound B positron emission tomography for solanezumab and placebo. Conclusions and Relevance This randomized clinical trial supports the importance of fibrillar amyloid reduction in multiple AD-related processes of neuroinflammation and neurodegeneration in CSF and plasma in DIAD. Additional studies of antiaggregated amyloid therapies in sporadic AD and DIAD are needed to determine the utility of nonamyloid biomarkers in determining disease modification. Trial Registration ClinicalTrials.gov Identifier: NCT04623242
30-Day complications, operative time, and overnight admission following elective elbow arthroscopy
El-Najjar, Dany , Mehta, Apoorva, Gupta, Puneet , Peterson, Joel R. , Rogalski, Brandon L. , Saltzman, Bryan M. , Marigi, Erick M. , El-Najjar, Dany B , Gupta, Puneet , Jobin, Charles M. , Trofa, David P

Mayo Clinic

Shoulder & Elbow | April 29, 2024 | Volume: 17 | Issue: 4 | Pages: 492-497

10.1177/17585732241249393 | PMID 39552679 Get It

Background Although arthroscopic procedures are generally considered safer than open procedures, they are not without complications. This study's purpose is to characterize patient demographics, medical complications, overnight admissions, and prolonged operative times for patients undergoing elective elbow arthroscopy using a national database. Methods This retrospective study used the ACS NSQIP database with data from 2015 to 2020. Patients undergoing elbow arthroscopy were identified, and those undergoing emergent surgery were excluded. Patient demographics, clinical characteristics, medical comorbidities, 30-day complications, overnight admission rates, and operative times were recorded and analyzed. Results Overall, 815 patients undergoing elective elbow arthroscopy were included. The mean age was 46.8 years. Mean BMI was 29.7 kg/m 2 , and 75.2% (n = 613) were male sex. The most common comorbidity was smoking (14.8%, n = 121). The cumulative complication rate was 2.5% (n = 20). The most common complication was surgical site infection (n = 7, 0.9%). 10.7% of patients required at least one overnight hospital stay. 20.2% of patients had a prolonged operative time ≥ 120 min. Conclusion Elbow arthroscopy is not without complications and morbidity despite being a minimally invasive procedure and advances made in surgical technique. Surgeons should use this information to facilitate shared-surgical decision making, preoperative patient counselling, and preoperative patient optimization.
Disproportionately high aortic valve calcium scores in atrial fibrillation: implications for transcatheter aortic valve replacement
Masson, Rajeev , Holmes, David R. , Klanderman, Molly, Abraham, Bishoy , Morsy, Mahmoud , Fortuin, F. David , Sweeney, John P., Sell-Dotten, Kristen, Alsidawi, Said , Alsidawi, Said , Nkomo, Vuyisile T. , Pislaru, Sorin V. , Arsanjani, Reza , Chao, Chieh‐Ju

Mayo Clinic

European Heart Journal - Cardiovascular Imaging | April 26, 2024 | Volume: 25 | Issue: 9 | Pages: 1264-1275

10.1093/ehjci/jeae113 | PMID 38669204 Get It

Abstract Aims Doppler mean gradient (MG) can underestimate aortic stenosis (AS) severity in patients with atrial fibrillation (AF) compared with patients with sinus rhythm (SR), potentially delaying intervention in AF. This study compared outcomes in patients with AF and SR following transcatheter aortic valve replacement (TAVR) and investigated delay in TAVR based on computed tomography aortic valve calcium score (AVCS). Methods and results Patients who underwent TAVR from 2013 to 2017 for native valve severe AS were identified from an institutional database. Baseline characteristics and overall survival were compared between those with SR and AF. There were 820 patients (mean age 81 years; 41.6% females) included in this study. AF was present in 356 patients. Patients with AF were older (82.2 vs. 80.5, P = 0.003) and had a lower MG compared with patients with SR (42.0 vs. 44.9, P = 0.002) with similar indexed aortic valve area (0.4 vs. 0.4, P = 0.17). Median AVCS was higher in AF (males: AF 2850.0 vs. SR 2561.0, P = 0.044; females: AF 1942.0 vs. SR 1610.5, P = 0.025). Projected AVCS, assuming the same age of diagnosis, was similar between AF and SR. Median survival post-TAVR was worse in AF compared with SR (3.2 vs. 5.4 years, log rank P < 0.001). AF, lower MG, higher right ventricular systolic pressure, dialysis, diabetes, and significant tricuspid regurgitation were associated with higher mortality (P < 0.05 for all). Conclusion Older age and higher AVCS in patients with AF compared with those with SR suggest that AS was both underestimated and more advanced at TAVR referral.
Five-Year Outcomes among U.S. Bronchiectasis and NTM Research Registry Patients
Aksamit, Timothy R. , Locantore, Nicholas , Ali, Juzar , Behrman, Megan, Brunton, Amanda E. , Chalmers, Sarah , Choate, Radmila , Dean, Nathan C. , DiMango, Angela, Fraulino, David , Johnson, Margaret M. , Lapinel, N. , McShane, Pamela J. , Miller, Bruce E. , Naureckas, Edward T. , O’Donnell, Anne E., Olivier, Kenneth N., Prusinowski, Elly, Richards, C. , Rhyne, Gloria, Thomashow, Byron, Tino, Gregory , Tsui, K., Varghese, Sumith Abraham, Warren, Heather E., Winthrop, Kevin , Zha, Beth Shoshanna, Addrizzo-Harris, Doreen , Basavaraj, Ashwin , Brunton, Amanda E , Chalmers, Sarah , Choate, Radmila , Dean, Nathan C , Johnson, Margaret M , Maselli, Diego J , McShane, Pamela J , Miller, Bruce E , O'Donnell, Anne E , Olivier, Kenneth N , Restrepo, Marcos I , Richards, Christopher J , Solomon, George M , Tal-Singer, Ruth , Zha, Beth Shoshanna , Addrizzo‐Harris, Doreen , BARKER, ALAN ROBERT , Metersky, Mark L. , Schmid, Andreas, Tal‐Singer, Ruth , Varghese, Sumith Abraham

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | April 26, 2024 | Volume: 210 | Issue: 1 | Pages: 108-118

10.1164/rccm.202307-1165oc | PMID 38668710 Get It

Abstract Rationale Nontuberculous mycobacteria (NTM) are prevalent among patients with bronchiectasis. However, the long-term natural history of patients with NTM and bronchiectasis is not well described. Objectives To assess the impact of NTM on 5-year clinical outcomes and mortality in patients with bronchiectasis. Methods Patients in the Bronchiectasis and NTM Research Registry with ⩾5 years of follow-up were eligible. Data were collected for all-cause mortality, lung function, exacerbations, hospitalizations, and disease severity. Outcomes were compared between patients with and without NTM at baseline. Mortality was assessed using Cox proportional hazards models and the log-rank test. Measurements and Main Results In total, 2,634 patients were included: 1,549 (58.8%) with and 1,085 (41.2%) without NTM at baseline. All-cause mortality (95% confidence interval) at Year 5 was 12.1% (10.5%, 13.7%) overall, 12.6% (10.5%, 14.8%) in patients with NTM, and 11.5% (9.0%, 13.9%) in patients without NTM. Independent predictors of 5-year mortality were baseline FEV1 percent predicted, age, hospitalization within 2 years before baseline, body mass index, and sex (all P < 0.01). The probabilities of acquiring NTM or Pseudomonas aeruginosa were approximately 4% and 3% per year, respectively. Spirometry, exacerbations, and hospitalizations were similar, regardless of NTM status, except that annual exacerbations were lower in patients with NTM (P < 0.05). Conclusions Outcomes, including exacerbations, hospitalizations, rate of loss of lung function, and mortality rate, were similar across 5 years in patients with bronchiectasis with or without NTM.
Visible Peristalsis in a Patient Referred for Chronic Intestinal Pseudo-Obstruction
Yang, David Yi , Cima, Robert R. , Jencks, Kara J. , Lupianez‐Merly, Camille , Camilleri, Michael , Cima, Robert , Jencks, Kara

Mayo Clinic

American Journal of Gastroenterology | April 26, 2024 | Volume: 120 | Issue: 1 | Pages: 26-26

10.14309/ajg.0000000000002838 | PMID 39745300 Get It

Delayed targeted atelectasis in a case of bronchoscopic lung volume reduction with endobronchial valves
Chandra, Nikitha C , Fernandez-Bussy, Isabel , Walsh, Katherine, Walsh, Katherine L, Abia‐Trujillo, David

Mayo Clinic

BMJ Case Reports | April 26, 2024 | Volume: 17 | Issue: 4 | Pages: e256573

10.1136/bcr-2023-256573 | PMID 38670566 Get It

A woman in her late 60s with severe chronic obstructive pulmonary disease (COPD) and emphysema underwent bronchoscopic lung volume reduction (BLVR) with endobronchial valves (EBV) to address hyperinflation. The initial EBV placement has led to partial lobar atelectasis of the left lower lobe and resulted in significant improvement in the patient’s symptoms and lung function. However, valve migration occurred later due to pneumothorax unrelated to valves, leading to suboptimal clinical improvement. The patient achieved delayed full lobar atelectasis 21 months after EBV placement, which led to a significant clinical improvement. The patient decided to be delisted from the lung transplant list due to the improvement. This case highlights the importance of considering delayed atelectasis as a possible outcome of EBV placement and suggests the need for further exploration of the long-term implications and associations of this procedure.
Physical impairment during and between migraine attacks: A daily diary study of patients with chronic migraine
Whitaker, David , Dumkrieger, Gina , Hentz, Joseph G. , Whitaker, David J , Dumkrieger, Gina , Dodick, David W. , Schwedt, Todd J.

Mayo Clinic

Cephalalgia | April 25, 2024 | Volume: 44 | Issue: 4 | Pages: No page available

10.1177/03331024241249747 | PMID 38663902 Get It

Objective While a substantial body of research describes the disabling impacts of migraine attacks, less research has described the impacts of migraine on physical functioning between migraine attacks. The objective of this study is to describe physical impairment during and between migraine attacks as a dimension of burden experienced by people living with chronic migraine. Methods The physical impairment domain of the Migraine Physical Function Impact Diary was recorded in headache diaries from the Medication Overuse Treatment Strategy trial. Days with moderate to severe headache were used to approximate migraine attacks. Factor analysis and regression analysis were used to describe associations between migraine and physical impairment. Results 77,662 headache diary entries from 720 participants were analyzed, including 25,414 days with moderate to severe headache, 19,149 days with mild headache, and 33,099 days with no headache. Mean physical impairment score was 41.5 (SD = 26.1) on days with moderate to severe headache, 12.8 (SD = 15.0) on days with mild headache, and 5.2 (SD = 13.1) on days with no headache. Physical impairment on days with mild headache and days with no headache was significantly associated with days since last moderate to severe headache, physical impairment with last moderate to severe headache, mild headache (compared to no headache), depression, hypersensitivities and cranial autonomic symptoms. Conclusions Physical impairment occurs on migraine and non-migraine days. Study participants with frequent headaches, symptoms of depression, hypersensitivities and cranial autonomic symptoms experience physical impairment at a higher rate on days with no headache and days with mild headache. Clinical Trial Registration: ClinicalTrials.gov (NCT02764320)
Echocardiographic findings in cancer-associated non-bacterial thrombotic endocarditis: clinical series of 111 patients from a single institution
Kurmann, Reto , Klarich, Kyle W. , Wysokinska, Ewa , Kamińska, Alicja , Patrzałek, Patryk , Hodge, David O. , Wysokiński, Waldemar E. , Kurmann, Reto D, Houghton, Damon, Patrzalek, Patryk, Hodge, David, Wysokinski, Waldemar , Houghton, Damon E.

Mayo Clinic

European Heart Journal - Cardiovascular Imaging | April 25, 2024 | Volume: 25 | Issue: 9 | Pages: 1255-1263

10.1093/ehjci/jeae112 | PMID 38662461 Get It

Abstract Aims Echocardiographic assessment of cancer-associated non-bacterial thrombotic endocarditis (Ca-NBTE) is limited to case reports and small clinical series. The study aimed to identify heart valve abnormalities and its relation to embolic complications and cancer types. Methods and results Manual review of echocardiographic images and medical records of Mayo Clinic patients (31 March 2002–30 June 2022) was performed. Ca-NBTE in 111 patients (mean age 63.2 ± 9.7 years, 66.7% female) predominantly affected mitral valves (MV) (69), 56 aortic (AV), 8 tricuspid (TV), and rarely pulmonic (PV) (1). In 18 patients, 2 valves were involved, 3 and 4 valve involvement in only a single patient each. Embolic complications were prevalent (n = 102, 91.9%). Ca-NBTE affected MV more frequently on the upstream (atrial) (90% vs. 49.3%) and TV downstream (ventricular) side (75% vs. 37.5%). NBTE size (cm) varied significantly among valves, with TV hosting the largest masses (0.63–2.40 × 0.39–1.77), compared with MV [(0.11–1.81 × 0.11–1.62), (length P = 0.001; width P = 0.03)] and AV [(0.20–2.70 × 0.11–1.51), (length P = 0.001; width P = 0.056)]; MV masses were borderline longer in systemic compared with cerebral emboli (P = 0.057). Majority of MV (79.6%) and AV (69.6%) had thickened leaflets. NBTE lesions commonly affected closing margins (73.9% MV, 85.7% AV, and 62.5% of TV) but rarely commissures of MV (8.7%), yet fairly frequently of AV (41.1%). Five patients had severe regurgitation of MV and 5 AV. Conclusion Ca-NBTE manifests mainly as thrombotic mobile masses attached to thickened MV and AV, with distinct variations in size based on valve type. Embolic destination but not cancer type is associated with NBTE mass size and location.
Ciliopathy patient variants reveal organelle-specific functions for TUBB4B in axonemal microtubules
Dodd, Daniel O , Mechaussier, Sabrina , Yeyati, Patricia L. , McPhie, Fraser , Anderson, Jacob R. , Khoo, Chen Jing , Shoemark, Amelia , Gupta, Deepesh Kumar , Attard, Thomas, Zariwala, Maimoona A. , Legendre, Marie , Bracht, Diana , Gui, Miao , Parry, David , Black, Holly A. , Mitri-Frangieh, Rana, Faucon, Catherine, Kaplan, Josseline, Megaw, Roly , Mohamed, Mai A., Aitken, Stuart , Gautier, Philippe , Reinholt, Finn R., Hirst, Robert A. , O’Callaghan, Chris, Bottier, Mathieu , Escudier, Estelle , Crowley, Suzanne , Descartes, Maria , Kenia, Priti , Amiel, Jeanne , Bacci, Giacomo Maria , Calogero, Claudia , Palazzo, Viviana , Tiberi, Lucia , Blümlein, Ulrike, Rogers, Andrew, Wenger, David A. , Fulton, Anne B. , Rosenfeld, Margaret , Holm, Ingrid A., Quigley, Alan J. , Murphy, Laura C. , Cassidy, Diane M. , Kriegsheim, Alex von , Partnership, Scottish Genomes, Network, Undiagnosed Diseases, Murris, Marlène , Hogg, Claire , Macleod, Kenneth , Urquhart, Don S. , Unger, Stefan , Amselem, Serge , Leigh, Margaret W. , Knowles, Michael R. , Mitchison, Hannah M. , Rozet, Jean‐Michel , Mill, Pleasantine , Gupta, Deepesh K , Wallmeier, Julia , Fassad, Mahmoud R , Tennant, Peter A , Meynert, Alison , Wheway, Gabrielle , Fares-Taie, Lucas , Black, Holly A , Patel, Mitali , McKie, Lisa , Megaw, Roly , Aitken, Stuart , Gautier, Philippe , Heimdal, Ketil , Bottier, Mathieu , Escudier, Estelle , Crowley, Suzanne , Descartes, Maria , Jabs, Ethylin W , Bacci, Giacomo Maria , Calogero, Claudia , Tiberi, Lucia , Wambach, Jennifer A , Wegner, Daniel J , Fulton, Anne B , Kenna, Margaret , Quigley, Alan , Hall, Emma A , Murphy, Laura C , Cassidy, Diane M , von Kriegsheim, Alex , Pasquier, Laurent , Murris, Marlène S , Chalmers, James D , Hogg, Claire , Macleod, Kenneth A , Urquhart, Don S , Unger, Stefan , Aitman, Timothy J , Leigh, Margaret W , Omran, Heymut , Mitchison, Hannah M , Brown, Alan , Marsh, Joseph A , Ti, Shih-Chieh , Horani, Amjad , Rozet, Jean-Michel , Perrault, Isabelle , Mill, Pleasantine , Dodd, Daniel O. , Mechaussier, Sabrina , Gatsogiannis, Christos , Holm, Ingrid A., Partnership, Scottish Genomes, Network, Undiagnosed Diseases, Papon, Jean‐François , Pasquier, Laurent , Chalmers, James D. , Omran, Heymut , Welburn, Julie P. I.

Mayo Clinic

Science | April 25, 2024 | Volume: 384 | Issue: 6694 | Pages: No page available

10.1126/science.adf5489 | PMID 38662826 Get It

Tubulin, one of the most abundant cytoskeletal building blocks, has numerous isotypes in metazoans encoded by different conserved genes. Whether these distinct isotypes form cell type– and context-specific microtubule structures is poorly understood. Based on a cohort of 12 patients with primary ciliary dyskinesia as well as mouse mutants, we identified and characterized variants in the TUBB4B isotype that specifically perturbed centriole and cilium biogenesis. Distinct TUBB4B variants differentially affected microtubule dynamics and cilia formation in a dominant-negative manner. Structure-function studies revealed that different TUBB4B variants disrupted distinct tubulin interfaces, thereby enabling stratification of patients into three classes of ciliopathic diseases. These findings show that specific tubulin isotypes have distinct and nonredundant subcellular functions and establish a link between tubulinopathies and ciliopathies.
Reply: Prospective Multicenter Evaluation of Pain Before and After Removal of Nonobstructing Renal Calculi: A CoRE Initiative
Bhojani, Naeem , Wollin, Daniel , Tayeb, Marawan M. El , Scotland, Kymora B. , Knoedler, John, Stern, Karen , Nguyen, David‐Dan , Rivera, Marcelino , Borofsky, Michael S. , Canvasser, Noah, Bechis, Seth K. , Hsi, Ryan S. , Stern, Karen L , Hsi, Ryan

Mayo Clinic

Journal of Urology | April 25, 2024 | Volume: 212 | Issue: 1 | Pages: 232-232

10.1097/ju.0000000000003956 | PMID 38661068 Get It